How big is the liver disease market | Global Analysis & Key Drivers 2025

How big is the Liver Disease Market?

The market is expanding due to rising prevalence of liver disorders, increasing alcohol consumption, growing obesity-related liver complications, and advances in diagnostics and treatment therapies.

Key Growth Drivers of the Liver Disease Market

• Increasing incidence of hepatitis, fatty liver disease, and liver cancer
• Rising alcohol consumption and lifestyle-related health risks
• Advancements in diagnostic imaging and non-invasive liver assessment
• Growing R&D in novel therapeutics and targeted drug delivery systems
• Expanding access to liver transplant procedures and specialized care

Liver Disease Market Trends

Liver disease market is witnessing trends such as the shift toward non-invasive diagnostic techniques like transient elastography, greater adoption of combination drug therapies, and expanding use of AI in imaging for early detection. Greater focus has been given to the screening of the people in the high-risk category; there are increased consultations over telemedicine related to the management of the chronic liver diseases. Future course of treatment is also being influenced by the rise in studies regarding regenerative medicine and bioengineered liver tissues.

Emerging Developments in the Liver Disease Market

Liver disease market is experiencing developments including the launch of next-generation antiviral drugs, gene therapy approaches for genetic liver disorders, and wider adoption of biosimilars in hepatitis treatment. Collaboration between drug firms and research organizations is also carrying out clinical studies of new compounds. Incorporation of wearable health tools on continuing monitoring and data gathering in real life circumstances is enhancing the patient’s outcomes, with the wide-ranging public health promotions raising the awareness and initial diagnosis rates.

List of Leading Companies in the Liver Disease Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Gilead Sciences, Inc.

Gilead Sciences develops antiviral and liver disease treatments, notably for hepatitis B and C, focusing on innovative therapies and expanding global patient access.

2. AbbVie Inc.

AbbVie offers a range of liver disease treatments, including hepatitis C antivirals, with strong R&D investments in fibrosis and non-alcoholic steatohepatitis (NASH).

3. Intercept Pharmaceuticals, Inc.

Intercept focuses on developing therapies for progressive non-viral liver diseases, with lead products targeting primary biliary cholangitis and NASH-related conditions.

4. Bristol Myers Squibb Company

Bristol Myers Squibb develops innovative treatments for liver fibrosis and hepatitis, leveraging immunotherapy and targeted small molecules to improve patient outcomes.

5. Novo Nordisk A/S

Novo Nordisk researches therapies for NASH and metabolic liver diseases, applying its expertise in metabolic disorders to target disease progression and complications.

6. Pfizer Inc.

Pfizer engages in liver disease drug development, with a focus on fibrosis and NASH, leveraging partnerships and novel mechanisms to address unmet medical needs.

7. F. Hoffmann-La Roche Ltd.

Roche develops diagnostics and therapeutics for viral hepatitis and liver cancer, integrating advanced molecular tools for early detection and personalized treatment.

8. Madrigal Pharmaceuticals, Inc.

Madrigal specializes in NASH therapies, focusing on metabolic and lipid-regulating drug candidates to improve liver health and reduce disease progression risks.

9. Merck & Co., Inc.

Merck develops antivirals and investigational drugs for hepatitis and liver cancer, combining immuno-oncology research with global access initiatives for patients.

10. Takeda Pharmaceutical Company Limited

Takeda advances therapies for chronic liver diseases, leveraging research in rare conditions, hepatocellular carcinoma, and inflammation-related hepatic disorders.

How big is the liver disease market : FAQs